Mitochondrial pharma-Q-genomics: targeting the OXPHOS cytochrome b

Drug Discov Today. 2011 Mar;16(5-6):176-80. doi: 10.1016/j.drudis.2010.11.010. Epub 2010 Nov 26.

Abstract

Genetic variation in human cytochrome b generates structurally different coenzyme Q binding pockets, affects the coupling efficiency of the oxidative phosphorylation system and susceptibility to different medical conditions. As modification of coupling efficiency has already been shown to have therapeutic interest, these structural differences might be used to develop new drugs and allow for personalized medicine, giving rise to a new field: mitochondrial pharmacogenomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Cytochromes b / genetics
  • Cytochromes b / metabolism*
  • Drug Delivery Systems
  • Drug Design
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Humans
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • Oxidative Phosphorylation
  • Pharmacogenetics / methods*
  • Precision Medicine / methods
  • Ubiquinone / metabolism*

Substances

  • Ubiquinone
  • Cytochromes b